echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > National consumables belt volume procurement began

    National consumables belt volume procurement began

    • Last Update: 2021-03-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    September 11, the official website of the State Health Insurance Administration announced that on September 10, drugs and high-value medical supplies centralized belt procurement symposium was held to study the deployment of drugs and high-value medical supplies centralized belt procurement work.The meeting showed that the centralized volume procurement reform has achieved remarkable results, and we should unswervingly push this work to a deeper level. To speed up the expansion of the scope of collection, efforts to crack the medical supplies standards are not the same, classification is not clear and other issues, do a solid job of heart stent concentration with volume procurement work.It also calls for strengthening the quality supervision of the whole life cycle of selected products, implementing "zero tolerance" for quality problems, and investigating and prosecuting them in accordance with the law. In accordance with the provisions of the procurement and use of selected drugs, consumables, to prevent the emergence of recruitment without picking, mining and not using.Qilu Pharmaceuticals, Lepu Medical Related Persons, experts from the Chinese Academy of Medical Sciences, Peking University First Hospital, Beijing Friendship Hospital affiliated with Capital Medical University, and relevant officials from the medical insurance departments of Tianjin and Anhui made presentations.According to Seber Blue Equipment previously reported that on July 3, the State Health Insurance Administration issued the "National Organization Crown Bracket Centralized Band Purchase Program (Draft for Comments)" shows that the public medical institutions will be the main body to carry out the crown vein stent centralized belt procurement, has launched its own crown vein stent volume procurement or no qualified medical institutions except in the provinces.The centralized volume purchase target is the crown vein stent product, which shall be approved by the drug regulatory department to obtain a valid medical device registration certificate material. The material is cobalt chromium alloy and platinum chromium alloy, the drug carrier type is repamycin or derivatives, the drug carrier coating properties of non-Teflon coronary stent.The above-mentioned draft for comments shows that in this volume procurement, in 2019 more than 1000 public medical institutions, military medical institutions should participate, other public medical institutions, military medical institutions, medical insurance fixed-point social-run medical institutions in accordance with the arrangements of their provinces to participate voluntarily.

    countries
    production bracket four giantit is understood that China's crown stent field has basically completed domestic replacement, including major foreign-funded enterprises including Medtron, Boston Science, Abbott, less than 30% of the domestic market share, domestic major enterprises including micro-invasive, Lepu, Jiwei, Sano Medical, the total market share of domestic manufacturers has exceeded 70%.Mininet data show that minimally invasane medical and Lepu medical market share of more than 20%, Jiwei medical market accounted for about 15%, Sano medical city accounted for about 10%, enterprise-related market layout and product information as follows.

    minimally invasAccording to the annual report, the micro-invasional medical cardiovascular business generated revenue of US$265 million (approximately RMB1.8 billion) in 2019, an increase of 35.5% over the previous year, accounting for 33.4% of total revenue.Revenue from minimally invascopic medical drug equip stents increased by 32.8% from 2018, with four drug equip stents and four balloon products on sale, including firehawkTM coronary repamycin targeted equip stent systems . FirehawkTM?) revenue increased 51.6% year-on-year, and Firebird 2TM coronary repamycin equip cobalt-based alloy stent system (?? Firebird2TM?) revenue increased 22.9% year-on-year.In addition to the rapid growth of the domestic market and the market recognition of the Firehawk bracket and the cost-effective Firebird bracket, the winning bid also boosted sales.

    Lepu MedicalAccording to the annual report, Lepu Medical Stent System achieved operating income of 1.79 billion yuan in 2019, up 26.71 percent year-on-year. Among them, crown support products achieved operating income of 1.53 billion yuan, up 23.34% YoY, and supporting auxiliary supplies (ball cystic catheters, guide wire, etc.) achieved operating income of 260 million yuan, up 50.95% YoY.During the reporting period, the proportion of the non-carrier drug stent system (Nano) in the metal stent sales structure was 46.05%.   NeoVas is selling well, with cases implanted in hundreds of hospitals in 29 provinces across the country, contributing to new performance growth, accounting for 10.24 per cent of crown stent sales structure.   Lepu Medical's core innovation is the Bio-absorbable Stent NeoVas Stent System, which was officially approved for registration by NMPA in February 2019, ushering in a new era of "involved implant-free" Lepu Medical PCI technology.

    Health Care   In 2018, BlueFan Medical acquired a 93.37 percent stake in Persein International Group for 5,895 million yuan, and Jiwei Medical is a subsidiary of Persein International. BlueFan Medical's annual report shows that during the reporting period, its cardiac intervention devices achieved operating income of 1.74 billion yuan, accounting for 49.99 percent of the company's total business revenue.   BlueFan Medical's Pershing International is the world's fourth largest heart stent research and development, production and sales company, after Abbott, Boston Science and Medtron, the crown stent market share is the fourth largest in the world, China's top three.   All kinds of stent products produced by Pershing International are sold to more than 90 countries and regions around the world, including bioFreedomTM, BioMatrixTM, Axel ® (EXCEL), EXCROSSAL and other flagship products, including drug-coated stents (DCS), drug wash-out stents (DES), bare metal stents and balloons and balloon catheters and other cardiac interventional surgery-related devices.   Among them, biodegradable coating drug empellation stent Exel ® (EXCEL) multi-year segment market share of 20%, for China's heart stent brand top three, since the market since the end of 2019 cumulative sales of more than 2.2 million.

    medical care in   According to the annual report, Sano Medical's main products are coronary drug stents and balloon catheters, with revenue of about 440 million yuan in 2019, up 14.5% YoY, and net profit of about 87 million yuan, down 0.07% YoY.   Sano Medical's main product, BuMA Biodegradable Drug Coating Coronary Stent System, was approved for sale in December 2010 and its market share has increased from 8.99% in 2015 to 11.62% in 2017.   Sano Medical said its next-generation BuMA Supreme stent products, as well as products such as the "thin-walled" magnesium alloy full-degradation bracket, will guarantee the company's continued profitability.
    (
    Cypress Blue Equipment
    )
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.